Gene therapy and intracytoplasmatic sperm injection (ICSI) - a review

Placenta. 2008 Oct:29 Suppl B:193-9. doi: 10.1016/j.placenta.2008.08.014.

Abstract

Human gene therapy (HGT), the treatment or prevention of disease by gene transfer is, regarded by many, as a potential revolution in medicine, because gene therapies target the causes of disease, whereas most current drugs treat the symptoms. Micro-assisted fertilization in the form of intracytoplasmatic sperm injection (ICSI) has truly revolutionized the treatment options for couples with impaired semen quality, and those with both obstructive and non-obstructive azoospermia. ICSI involves the injection of a single sperm directly into the cytoplasm of a mature egg (oocyte) using a glass needle (pipette). Fertilization with this technique occurs in 50%-80% of injected oocytes, but may damage a small percentage of them. With gene therapy, there are new and varied strategies for gene transfer and genome sequence manipulation with improved methodologies that use the technique of microinjection such as the intracytoplasmatic sperm injection-mediated transgenesis (ICSI-Tr), active transgenesis or the pronuclear microinjection technique. This review will look at these methods as well as their potential applications and limitations.

Publication types

  • Evaluation Study
  • Review

MeSH terms

  • Female
  • Gene Targeting / methods
  • Gene Transfer Techniques
  • Genetic Therapy / methods*
  • Humans
  • Infertility / therapy*
  • Male
  • Sperm Injections, Intracytoplasmic / methods*
  • Transgenes / physiology